Vitae Pharmaceuticals (VTAE) Getting Favorable Press Coverage, Report Shows

Media headlines about Vitae Pharmaceuticals (NASDAQ:VTAE) have trended positive on Saturday, Alpha One reports. Alpha One, a service of Accern, rates the sentiment of news coverage by reviewing more than twenty million news and blog sources in real time. Alpha One ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Vitae Pharmaceuticals earned a media sentiment score of 0.44 on Alpha One’s scale. Alpha One also gave news headlines about the biotechnology company an impact score of 0 out of 100, indicating that recent news coverage is extremely unlikely to have an effect on the company’s share price in the immediate future.

Shares of Vitae Pharmaceuticals (NASDAQ:VTAE) remained flat at $21.00 during midday trading on Friday. The stock’s 50-day moving average price is $18.81 and its 200 day moving average price is $11.50. Vitae Pharmaceuticals has a 12 month low of $4.08 and a 12 month high of $21.03.

WARNING: “Vitae Pharmaceuticals (VTAE) Getting Favorable Press Coverage, Report Shows” was first posted by Transcript Daily and is owned by of Transcript Daily. If you are viewing this report on another domain, it was illegally copied and reposted in violation of U.S. & international copyright & trademark legislation. The correct version of this report can be read at

Vitae Pharmaceuticals Company Profile

Vitae Pharmaceuticals, Inc is a biotechnology company. The Company is focused on discovering and developing small molecule drugs for diseases. It is engaged in developing a portfolio of product candidates through Contour, its structure-based drug discovery platform. The Company’s product candidates include VTP- 43742 for the treatment of psoriasis, as well as multiple other autoimmune disorders.

Receive News & Ratings for Vitae Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vitae Pharmaceuticals Inc and related companies with's FREE daily email newsletter.

Leave a Reply